Nucleus empowers practitioners, patients, and investors to grow in the psychedelics industry.
We'll send you updates on everything we launch, including our published content and data reports.
Nucleus is actively working on tools, platforms, and assets that help to educate the masses and support the psychedelic renaissance.
In August 2022 alone, over five million people searched “psychedelics” on Google, and, in 2019, $17 million was invested into Johns Hopkins to fund psychedelic research.
The Nucleus community has over 50,000 members that contribute to over 100,000 pageviews per month.
Nucleus is a diverse ecosystem with many different companies and brands that lead to a unique world of psychedelic medicine investments.
We're comprised of experienced individuals that are passionate about helping as many people as possible and bringing psychedelic treatments to the forefront.
We make it easy for third parties to “plug and pull” the data and tools in real time. The hub-and-spoke layout also allows for more efficient two-way interactions between entities and data points.
Neuly distributes this psychedelics-related data through integrations and an API.
Nucleus allows for everyone from patients, investors, and healthcare professionals to access and utilize information.
The Psychedelic Invest podcast has published two seasons filled with industry experts and compelling origin stories. Join the thousands of listeners and get to know the brilliant stakeholders pushing this industry forward. You can listen to the 20+ episodes anywhere that podcasts are available.
Weekly reviews of the psychedelics market and the companies operating within it. This has allowed the Psychedelic Invest YouTube channel to become one of the most popular in the psychedelics industry regarding investments.
We have several powerful plans to showcase your business and get discovered as a creative entrepreneurs
Before you invest, it's important you understand everything there is to know about Nucleus and equity crowdfunding as a whole.
Let Nucleus connect you with the psychedelics industry, today.